Scale for the assessment and rating of ataxia

By T. Schmitz-Hübsch, S. D. Montcel, L. Balikó, J. Berciano, S. Boesch, C. Depondt, P. Giunti, C. Globas, J. Infante, J-S Kang and 13 more. Neurology, 2006

1,548 citations recorded by the source corpus.

Objective: To develop a reliable and valid clinical scale measuring the severity of ataxia. Methods: The authors devised the Scale for the Assessment and Rating of Ataxia (SARA) and tested it in two trials of 167 and 119 patients with spinocerebellar ataxia. Results: The mean time to administer SARA in patients was 14.2 ± 7.5 minutes (range 5 to 40). Interrater reliability was high, with an intraclass coefficient (ICC) of 0.98. Test-retest reliability was high with an ICC of 0.90. Internal consistency was high as indicated by Cronbach's α of 0.94. Factorial analysis revealed that the rating results were determined by a single factor. SARA ratings showed a linear relation to global assessments using a visual analogue scale, suggesting linearity of the scale (p < 0.0001, r2 = 0.98). SARA score increased with the disease stage (p < 0.001) and was closely correlated with the Barthel Index (r = −0.80, p < 0.001) and part IV (functional assessment) of the Unified Huntington's Disease Rating Scale (UHDRS-IV) (r = −0.89, p < 0.0001), whereas it had only a weak correlation with disease duration (r = 0.34, p < 0.0002) Conclusions: The Scale for the Assessment and Rating of Ataxia is a reliable and valid measure of ataxia, making it an appropriate primary outcome measure for clinical trials.

Subfields: Cellular and Molecular Neuroscience, Neurology

View Paper: https://www.semanticscholar.org/paper/9b14e49d87211d2d1159e1bacf5c01b26fd18806